Fig. 1: Summary of the relationship between MDS patients’ subtypes defined in the WHO 2016 and WHO 2022 classification. | Leukemia

Fig. 1: Summary of the relationship between MDS patients’ subtypes defined in the WHO 2016 and WHO 2022 classification.

From: Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms

Fig. 1

WHO World Health Organization, MDS myelodysplastic syndromes(neoplasms), MDS-U MDS unclassifiable, SLD single lineage dysplasia, MLD multilineage dysplasia, RS-SLD ring sideroblasts with SLD, RS-MLD ring sideroblasts with MLD, EB1/2 excess blasts type 1/2, 5q- isolated 5q deletion, biTP53 biallelic TP53 inactivation, LB low blasts, MDS-SF3B1 MDS with low blasts and SF3B1 mutation, MDS-h MDS, hypoplastic, IB1/2 increased blasts type1/2, MDS-f MDS with fibrosis.

Back to article page